Last reviewed · How we verify
IGIV GAMMAGARD LIQUID/KIOVIG
IGIV GAMMAGARD LIQUID/KIOVIG is a Intravenous immunoglobulin (IGIV) Biologic drug developed by Baxalta now part of Shire. It is currently in Phase 3 development for Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency), Secondary immunodeficiency in hematologic malignancies, Chronic inflammatory demyelinating polyneuropathy (CIDP). Also known as: Immune Globulin Infusion (Human), Intravenous immunoglobulin G, 10% (GAMMAGARD LIQUID/KIOVIG), GAMMAGARD LIQUID.
IGIV (intravenous immunoglobulin) provides passive immunity by supplying pooled human antibodies to replace or supplement deficient or dysfunctional immunoglobulin in patients with immune deficiencies or autoimmune conditions.
IGIV (intravenous immunoglobulin) provides passive immunity by supplying pooled human antibodies to replace or supplement deficient or dysfunctional immunoglobulin in patients with immune deficiencies or autoimmune conditions. Used for Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency), Secondary immunodeficiency in hematologic malignancies, Chronic inflammatory demyelinating polyneuropathy (CIDP).
At a glance
| Generic name | IGIV GAMMAGARD LIQUID/KIOVIG |
|---|---|
| Also known as | Immune Globulin Infusion (Human), Intravenous immunoglobulin G, 10% (GAMMAGARD LIQUID/KIOVIG), GAMMAGARD LIQUID |
| Sponsor | Baxalta now part of Shire |
| Drug class | Intravenous immunoglobulin (IGIV) |
| Target | Fc receptors, complement system, pathogenic antigens |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IGIV is a preparation of concentrated immunoglobulin G (IgG) derived from pooled human plasma that contains a broad spectrum of antibodies against common pathogens. It works by providing immediate passive immunity, opsonizing pathogens, activating complement, and modulating immune responses through Fc receptor engagement. This helps prevent infections in immunocompromised patients and can suppress pathogenic autoimmune responses in certain conditions.
Approved indications
- Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)
- Secondary immunodeficiency in hematologic malignancies
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Multifocal motor neuropathy
- Idiopathic thrombocytopenic purpura (ITP)
- Post-transfusion purpura
- Kawasaki disease
Common side effects
- Headache
- Fever
- Chills
- Fatigue
- Myalgia
- Nausea
- Infusion site reactions
- Aseptic meningitis
- Thromboembolism
Key clinical trials
- A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma (PHASE3)
- A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (PHASE3)
- Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy (PHASE3)
- A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease (PHASE3)
- Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID (PHASE3)
- Gammagard Liquid and rHuPH20 in PID (PHASE3)
- Immune Globulin Subcutaenous (Human), 20% (PHASE2, PHASE3)
- LIME Study (LFB IVIg MMN Efficacy Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGIV GAMMAGARD LIQUID/KIOVIG CI brief — competitive landscape report
- IGIV GAMMAGARD LIQUID/KIOVIG updates RSS · CI watch RSS
- Baxalta now part of Shire portfolio CI
Frequently asked questions about IGIV GAMMAGARD LIQUID/KIOVIG
What is IGIV GAMMAGARD LIQUID/KIOVIG?
How does IGIV GAMMAGARD LIQUID/KIOVIG work?
What is IGIV GAMMAGARD LIQUID/KIOVIG used for?
Who makes IGIV GAMMAGARD LIQUID/KIOVIG?
Is IGIV GAMMAGARD LIQUID/KIOVIG also known as anything else?
What drug class is IGIV GAMMAGARD LIQUID/KIOVIG in?
What development phase is IGIV GAMMAGARD LIQUID/KIOVIG in?
What are the side effects of IGIV GAMMAGARD LIQUID/KIOVIG?
What does IGIV GAMMAGARD LIQUID/KIOVIG target?
Related
- Drug class: All Intravenous immunoglobulin (IGIV) drugs
- Target: All drugs targeting Fc receptors, complement system, pathogenic antigens
- Manufacturer: Baxalta now part of Shire — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Primary immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable immunodeficiency)
- Indication: Drugs for Secondary immunodeficiency in hematologic malignancies
- Indication: Drugs for Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Also known as: Immune Globulin Infusion (Human), Intravenous immunoglobulin G, 10% (GAMMAGARD LIQUID/KIOVIG), GAMMAGARD LIQUID
- Compare: IGIV GAMMAGARD LIQUID/KIOVIG vs similar drugs
- Pricing: IGIV GAMMAGARD LIQUID/KIOVIG cost, discount & access